SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-097728
Filing Date
2024-04-16
Accepted
2024-04-16 16:06:04
Documents
14
Period of Report
2024-04-10
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d769681d8k.htm   iXBRL 8-K 25101
5 GRAPHIC g769681g0416091639962.jpg GRAPHIC 2767
  Complete submission text file 0001193125-24-097728.txt   155660

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240410.xsd EX-101.SCH 2890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240410_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240410_pre.xml EX-101.PRE 11288
18 EXTRACTED XBRL INSTANCE DOCUMENT d769681d8k_htm.xml XML 3669
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 24847844
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)